Navigation Links
Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
Date:1/7/2009

UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists would welcome an adjunctive antiepileptic drug (AED) that is administered once-daily. According to U.S. neurologists, a drug of this type would earn a 25 percent patient share in epilepsy and according to European neurologists, such an agent would earn 35 percent patient share. According to the new report entitled Epilepsy: Opportunity Exists for Improved AEDs Despite Numerous Market Pressures, these robust patient shares highlight surveyed neurologists' keen interest in AEDs with less-frequent dosing. Nevertheless, these patient shares are considerably higher than those typically attained by adjunctive AEDs, given neurologists' generally conservative adoption of new epilepsy therapies as well as adjunctive AEDs' use primarily in refractory patients. Consequently, it is not expected that emerging adjunctive AEDs will capture such generous patient shares.

The report also finds that UCB's Keppra XR will earn Decision Resources' proprietary clinical gold standard status for the adjunctive treatment of partial-onset epilepsy by 2012 as interviewed specialists indicate that the drug has competitive advantages in safety and delivery attributes over GlaxoSmithKline's sales-leading Lamictal. According to surveyed neurologists, Keppra XR is perceived as having a lower risk of serious side effects and offers the advantage of once-daily dosing, which is considered to be the ideal AED dosing frequency for epilepsy patients.

"With its high cost and the high level of physician comfort in prescribing the drug as an add-on therapy, Lamictal became the epilepsy sales leader in 2007, ahead of the 2007 clinical gold standard immediate-release Keppra," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "However, Keppra XR, which has now launched in the United States, provides improved convenience over both Lamictal and immediate-release Keppra while retaining a favorable efficacy and safety and tolerability profile."

About the Report

Epilepsy: Opportunity Exists for Improved AEDs Despite Numerous Market Pressures is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help clients optimize their investments in drug development. Driven by quantitative and qualitative primary research, DecisionBase 2009 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. Each report provides detailed market share, patient share and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Heather Hilty                                Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2536                                 781-296-2563
    hhilty@dresources.com                        emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms
4. Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients
5. Eligard(R) six-month formulation successfully completes European approval procedure
6. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
7. Medical Services International Inc. Completes Testing for European Union (EU) Application
8. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
9. Europe-wide Researchers Night
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Launch of second European Cancer Research Funding survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Sideline Products is a Southern York County ... the smaller rider and the horse. Smaller saddles can pinch and irritate the horse ... fit over a properly fitted western saddle so it does not impact the comfort ...
(Date:12/5/2016)... ... ... “Life Will Never Be The Same” is a fictional tale about growing up with ... is the creation of published author, Kim T. Briggs, a self-described “big kid” who ... religion and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama ...
(Date:12/5/2016)... ... , ... Sabah Shah MD, MBA has joined the Retina Group of New York ... by James M. Maisel, MD and has been providing tertiary medical and surgical retinal care ... of surpassing expectations amongst her peers. Growing up in a family of doctors, Dr. ...
(Date:12/5/2016)... Greifensee, Switzerland (PRWEB) , ... ... ... testing between professional calibrations is an excellent way to ensure moisture measurements ... methods are time-consuming and impractical. , Now, METTLER TOLEDO offers a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... December 5, 2016 BioLineRx Ltd. (NASDAQ/TASE: ... developing promising therapeutic candidates, presents positive Phase 2a correlative data, ... leading oncology platform at the ongoing 58th American Society of ... Diego, California . ... , , As ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology: